GLP-1 RA antiobesity medications: Talking about cost

Author(s):

Richard Payerchin

Key Takeaways

GLP-1 receptor agonists are effective for obesity treatment but are associated with high costs, impacting patient access.
Physicians should engage in transparent discussions with patients about the financial implications of GLP-1 RAs.
Dr. Robert Kushner highlights the importance of balancing treatment efficacy with affordability and accessibility for patients.
Experience in research and clinical practice informs strategies for addressing financial barriers in obesity treatment.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

The new GLP-1 RA drugs are effective – and expensive. How should physicians talk about this with patients? Robert Kushner, MD, discusses the financial factors that affect patient treatment for obesity. He has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.